GlassScriptPhysician profile
Joshua W Eberhard
NPI 1629339692
$6,435.56
in general payments reported to CMS, 2019-2025
37 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,710 · 2020: $462 · 2021: $223 · 2022: $290 · 2023: $1,345 · 2024: $1,288 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,751.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $949.11 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $781.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $506.69 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $478.85 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.72 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $416.48 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $368.83 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $354.52 | 2019-2025 | |
| Exact Sciences Corporation | $278.15 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $256.20 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.77 | 2019-2025 | Xifaxan |
| Dynavax Technologies Corporation | $151.97 | 2022-2025 | Heplisav-B |
| Merck Sharp & Dohme LLC | $146.74 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Phathom Pharmaceuticals, INC. | $117.96 | 2024 | Voquezna |
| Abbott Laboratories | $109.51 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $102.77 | 2019-2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $96.70 | 2022-2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $76.68 | 2025 | |
| Amarin Pharma, INC. | $74.09 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.16 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $66.58 | 2019-2020 | |
| Allergan, INC. | $64.40 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.05 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $46.38 | 2023 | Rexulti |
| Arbor Pharmaceuticals, INC. | $31.40 | 2019-2020 | |
| Lucid Diagnostics INC. | $24.57 | 2023 | |
| Si-Bone, INC. | $23.15 | 2024 | |
| Renalytix Ai, INC. | $21.40 | 2022 | |
| Inspire Medical Systems, INC. | $20.56 | 2025 | Inspire |
| Gilead Sciences, INC. | $19.79 | 2025 | |
| Upsher-Smith Laboratories LLC | $19.75 | 2019 | |
| Almatica Pharma LLC | $18.76 | 2023 | Gralise |
| Nevro Corp. | $17.65 | 2023 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $16.40 | 2022 | |
| Phadia US INC. | $16.34 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.13 | 2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Eberhard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.